ABSTRACT
Purpose@#Appropriate preclinical mouse models are needed to evaluate the response to immunotherapeutic agents. Immunocompetent mouse models have rarely been reported for gastric cancer. Thus, we investigated immunophenotypes and responses to immune checkpoint inhibitor (ICI) in immunocompetent mouse models using various murine gastric cancer cell lines. @*Materials and Methods@#We constructed subcutaneous syngeneic tumors with murine gastric cancer cell lines, YTN3 and YTN16, in C57BL/6J mice. Mice were intraperitoneally treated with IgG isotype control or an anti–programmed death-ligand 1 (PD-L1) neutralizing antibody. We used immunohistochemistry to evaluate the tumor-infiltrating immune cells of formalin-fixed paraffin-embedded mouse tumor tissues. We compared the protein and RNA expression between YTN3 and YTN16 cell lines using a mouse cytokine array and RNA sequencing. @*Results@#The mouse tumors revealed distinct histological and molecular characteristics. YTN16 cells showed upregulation of genes and proteins related to immunosuppression, such as Ccl2 (CCL2) and Csf1 (M-CSF). Macrophages and exhausted T cells were more enriched in YTN16 tumors than in YTN3 tumors. Several YTN3 tumors were completely regressed by the PD-L1 inhibitor, whereas YTN16 tumors were unaffected. Although treatment with a PD-L1 inhibitor increased infiltration of T cells in both the tumors, the proportion of exhausted immune cells did not decrease in the non-responder group. @*Conclusion@#We confirmed the histological and molecular features of cancer cells with various responses to ICI. Our models can be used in preclinical research on ICI resistance mechanisms to enhance clinical efficacy.
ABSTRACT
Purpose@#Coronavirus disease-2019 (COVID-19) is a novel respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); there are few specific treatments. Convalescent plasma (CP), donated by people who have recovered from COVID-19, is an investigational therapy for severe or critically ill patients with COVID-19. @*Materials and Methods@#This retrospective cohort study evaluated the effectiveness of CP therapy in patients with severe or lifethreatening cases of COVID-19 at two hospitals in Seoul, Korea, between May and September 2020. Clinical outcomes were evaluated in 20 patients with CP therapy in a descriptive manner. Additionally, the changes in cycle threshold (Ct) values of 10 patients with CP therapy were compared to those of 10 controls who had the same (±0.8) initial Ct values but did not receive CP. @*Results@#Of the 20 patients (mean age 66.6 years), 18 received high-dose oxygen therapy using mechanical ventilators or high-flow nasal cannulas. Systemic steroids were administered to 19 patients who received CP. The neutralizing antibody titers of the administered CP were between 1:80 and 1:10240. There were two ABO-mismatched transfusions. The World Health Organization ordinal scale score and National Institutes of Health severity score improved in half of the patients within 14 days. Those who received CP showed a higher increase in Ct values at 24 h and 72 h after CP therapy compared to controls with similar initial Ct values (p=0.002).No transfusion-related side effects were observed. @*Conclusion@#CP therapy may be a potential therapeutic option in severe or critically ill patients with COVID-19.
ABSTRACT
Purpose@#Coronavirus disease-2019 (COVID-19) is a novel respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); there are few specific treatments. Convalescent plasma (CP), donated by people who have recovered from COVID-19, is an investigational therapy for severe or critically ill patients with COVID-19. @*Materials and Methods@#This retrospective cohort study evaluated the effectiveness of CP therapy in patients with severe or lifethreatening cases of COVID-19 at two hospitals in Seoul, Korea, between May and September 2020. Clinical outcomes were evaluated in 20 patients with CP therapy in a descriptive manner. Additionally, the changes in cycle threshold (Ct) values of 10 patients with CP therapy were compared to those of 10 controls who had the same (±0.8) initial Ct values but did not receive CP. @*Results@#Of the 20 patients (mean age 66.6 years), 18 received high-dose oxygen therapy using mechanical ventilators or high-flow nasal cannulas. Systemic steroids were administered to 19 patients who received CP. The neutralizing antibody titers of the administered CP were between 1:80 and 1:10240. There were two ABO-mismatched transfusions. The World Health Organization ordinal scale score and National Institutes of Health severity score improved in half of the patients within 14 days. Those who received CP showed a higher increase in Ct values at 24 h and 72 h after CP therapy compared to controls with similar initial Ct values (p=0.002).No transfusion-related side effects were observed. @*Conclusion@#CP therapy may be a potential therapeutic option in severe or critically ill patients with COVID-19.
ABSTRACT
Background and Objectives@#Steroids have strong anti-inflammatory, anti-edema, and antipyretic effects. Since there are few studies on the use of steroids in the treatment of peritonsillar abscess in Korea, we aimed at this study to investigate the effects of steroids along with antibiotics in the treatment of peritonsillar abscess.Subjects and Method A retrospective study was conducted on 75 patients who were admitted from 2014 to 2019. Between 2014 and 2017, only antibiotics were administrated after incisional drainage (no-use group), but between 2018 and 2019, antibiotics and adjunctive steroids were administrated after incisional drainage (steroids group). Symptoms of patients, blood tests, diets available, and hospitalization period were compared between the two groups. @*Results@#The length of hospital stay for the steroids group (n=24) and the no-use group (n=51) was 4.2±1.3 days and of 5.1±1.8 days (p=0.046), respectively, showing significantly shortened time for the steroids group. The rate of change in 48-hour C-reactive protein was 53.3% and 20% for the steroid group and no-use group (p=0.013), respectively. However, there was no differences between the two groups in the rate of change in body temperature at 12 hours of treatment, the diet available at 12 hours, and rate of change in the number of white blood cells after 48 hours of treatment. @*Conclusion@#Adjunctive steroids for peritonsillar abscess can be a useful treatment that shows rapid improvement of symptoms and C-reactive protein, and shorter hospitalization periods.